Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

被引：10

作者：

Pipe, Steven W. ^{[1
]}

Collins, Peter ^{[2
]}

Dhalluin, Christophe ^{[3
]}

Kenet, Gili ^{[4
,5
]}

Schmitt, Christophe ^{[3
]}

Buri, Muriel ^{[3
]}

Jimenez-Yuste, Victor ^{[6
]}

Peyvandi, Flora ^{[7
,8
,9
]}

Young, Guy ^{[10
]}

Oldenburg, Johannes ^{[11
]}

Mancuso, Maria Elisa ^{[12
]}

Kiialainen, Anna ^{[3
]}

Chang, Tiffany ^{[13
]}

Lehle, Michaela ^{[3
]}

Fijnvandraat, Karin ^{[14
]}

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Cardiff Univ, Sch Med, Cardiff, Wales

[3] F Hoffmann La Roche Ltd, Basel, Switzerland

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain

[7] Fdn IRCCS CaGranda Osped Maggiore Policlin, Angelo Bianchi Bon Hemophilia, Milan, Italy

[8] Thrombosis Ctr, Milan, Italy

[9] Univ Milan, Milan, Italy

[10] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA

[11] Univ Bonn, Bonn, Germany

[12] IRCCS Humanitas Res Hosp, Rozzano, Italy

[13] Spark Therapeut Inc, San Francisco, CA USA

[14] Univ Amsterdam, Amsterdam, Netherlands

来源：

关键词：

D O I：

10.1182/blood-2022-157264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3